SIRPα-Fc fusion protein

SIRPα-Fc fusion protein is a recombinant therapeutic protein designed to block the CD47-SIRPα signaling axis, a critical myeloid checkpoint. CD47 is a cell-surface protein that functions as a "don't eat me" signal by binding to Signal Regulatory Protein Alpha (SIRPα) on macrophages and other phagocytes, thereby inhibiting phagocytosis. In cardiovascular diseases such as myocardial infarction and atherosclerosis, CD47 is often upregulated on dying cardiomyocytes or within vascular plaques, impairing the efficient clearance of cellular debris (efferocytosis) and promoting chronic inflammation. This fusion protein, typically comprising the extracellular CD47-binding domain of SIRPα fused to an immunoglobulin Fc region, acts as a decoy receptor to sequester CD47 and restore phagocytic activity. Developed by Bitterroot Bio (specifically as the high-affinity variant BRB-001), this agent has demonstrated the ability to reduce infarct size, improve cardiac contractility, and attenuate atherosclerosis progression in preclinical models by enhancing macrophage-mediated resolution of inflammation.

Other names

anti-CD47 fusion proteinanti-CD-47 fusion proteinanti-CD 47 fusion proteinSIRPA-Fc fusion protein